Author

Na Chen

East China University of Science and TechnologyORCID 0000-0003-0066-2082Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Na Chen2 papers · Chinese Academy of Sciences

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:deep learning· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:metabolomics· 1

Frequent Co-Authors

Rui WangiD· 2 shared Shiliang LiiD· 2 shared Tianyu Ye· 2 shared Bowen KeiD· 1 shared Chang LiuiD· 1 shared Feng Hu· 1 shared Hanqing ZhaoiD· 1 shared Honglin LiiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Rui WangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistrybioRxivPreprintJan 5, 2026

TRPV4 Inhibition by a Natural Product Mediates Analgesia

Zhen Yuan, Jie Qiu, Shiliang Li…·Bowen Ke

This study identifies AH001 as a potent TRPV4 inhibitor, revealing its mechanism and demonstrating its analgesic effects in pain models.

1 citation

experimental assaydrug response / drug discovery

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJun 2, 2025

Contrastive Learning-Enhanced Drug Metabolite Prediction Drives the Discovery of an Orally Bioavailable RSK4 Inhibitor for Esophageal Cancer

Huan He, Manzhan Zhang, Xiaoxiao Yang…·Shiliang Li

The paper develops ConMeter, a metabolite prediction model, and uses it to design an orally bioavailable RSK4 inhibitor with improved bioavailability and anti-tumor efficacy against esophageal cancer.

2 citations

humanmetabolomics

𝕏 PostBluesky